Nievergall et al. described in 2014 the potential of a humanized monoclonal antibody against CD123 (CSL362) for the treatment of chronic myeloid leukemia (CML) through depletion of CM progenitor and stem cells [161]. This evidence concerns the gene IL3RA and chronic myelogenous leukemia, BCR-ABL1 positive.